Teladoc Health Held In-Line Rating in Late Ocotber as Evercore Reversed Price Target Back to $8
In October 2025, Evercore ISI analyst Elizabeth Anderson issued two ratings on Teladoc Health, both times maintaining an In-Line stance while adjusting the firm's price target in opposite directions.







